Mark Manfredi, Ikena Oncology CEO
August 7, 2023 09:07 AM EDTUpdated 10:24 AM
Startups
Deals

Ike­na inks small cash grab in all-stock deal for Pi­o­nyr to take can­cer drug on Hip­po path­way

Kyle LaHucik

Senior Reporter

Ike­na On­col­o­gy said it added about $43 mil­lion to its run­way af­ter mak­ing an all-stock ac­qui­si­tion of the pri­vate start­up Pi­o­nyr …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times